newsfilter
← Latest News
GlobeNewswire·

Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001

- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity...